Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

9784	Companies
195990	Keywords
127049	Articles
104229	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 03/19/2024 at 07:05, 1 year 10 months ago

Newron Pharmaceuticals SpA annonce ses résultats financiers pour 2023 et fournit des perspectives pour 2024

Perspectives 2024 Résultats Financiers 2023 Produits Pharmaceutiques Newron Xadago Safinamide Développement D'Evenamide
BRIEF

published on 03/19/2024 at 07:05, 1 year 10 months ago

Newron Pharmaceuticals S.p.A. Announces 2023 Financial Results and Provides Outlook for 2024

2024 Outlook Financial Results 2023 Newron Pharmaceuticals Evenamide Development Xadago Safinamide
PRESS RELEASE

published on 03/19/2024 at 07:00, 1 year 10 months ago

Newron presents 2023 financial results and provides 2024 outlook
Newron Pharmaceuticals S.p.A. presents 2023 financial results and 2024 outlook, including advancements in schizophrenia treatment and strategic partnerships

Financial Results 2024 Outlook Partnerships Newron Pharmaceuticals Schizophrenia Treatment
BRIEF

published on 03/15/2024 at 07:05, 1 year 10 months ago

Newron Pharmaceuticals SpA annonce un accord de remboursement modifié avec la Banque européenne d'investissement

Produits Pharmaceutiques Newron Evenamide Banque Européenne D'investissement Accord De Financement Traitements Du SNC
BRIEF

published on 03/15/2024 at 07:05, 1 year 10 months ago

Newron Pharmaceuticals S.p.A. Announces Amended Repayment Agreement with European Investment Bank

European Investment Bank Newron Pharmaceuticals Financing Agreement Evenamide CNS Treatments
PRESS RELEASE

published on 03/15/2024 at 07:00, 1 year 10 months ago

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Newron Pharmaceuticals S.p.A. agrees with EIB to extend repayment dates of 2018 financing agreement tranches after pipeline milestones

European Investment Bank Financing Agreement Evenamide Newron Pharmaceuticals S.p.A. Loan Repayment Dates
BRIEF

published on 03/14/2024 at 18:37, 1 year 10 months ago

Newron Pharmaceuticals obtient jusqu'à 15 millions d'euros de financement grâce à l'émission de nouvelles actions

Émission D'actions Produits Biopharmaceutiques Accord D'investissement Produits Pharmaceutiques Newron Thérapies Du SNC
BRIEF

published on 03/14/2024 at 18:37, 1 year 10 months ago

Newron Pharmaceuticals Secures Up to EUR 15 Million in Funding Through New Share Issuance

Share Issuance Biopharmaceuticals Investment Agreement Newron Pharmaceuticals CNS Therapies
PRESS RELEASE

published on 03/14/2024 at 18:32, 1 year 10 months ago

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
Newron Pharmaceuticals S.p.A. enters a subscription agreement for up to 2.05 million new shares, aiming to raise EUR 15.0 million. The investment supports CNS therapies development

Subscription Agreement Newron Pharmaceuticals Newly Issued Shares EUR 15.0 Million CNS Therapies Development
PRESS RELEASE

published on 10/09/2023 at 12:45, 2 years 3 months ago

Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria

Accesswire

Published on 02/02/2026 at 15:00, 6 hours 4 minutes ago

Jericho Energy Ventures Strategically Terminates SmartKem LOI to Advance Independent Data Center Energy Infrastructure Platform
Published on 02/02/2026 at 14:30, 6 hours 34 minutes ago

Unusual Machines Promotes Drew Camden to President
Published on 02/02/2026 at 14:30, 6 hours 34 minutes ago

Predictiv AI Provides Pilot Update from Innovate Calgary's Soaring Higher Challenge with Calgary Airports and WestJet
Published on 02/02/2026 at 14:30, 6 hours 34 minutes ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
Published on 02/02/2026 at 14:00, 7 hours 4 minutes ago

Paymetrex Launches Patent Licensing Program to Monetize Mobile Payments IP Portfolio

View all ACCESSWIRE

EQS Group

Published on 02/02/2026 at 20:00, 1 hour 4 minutes ago

CGTN AMERICA & CCTV UN: Cultural Event Celebrating the Spring Festival and the 55th Anniversary of China-U.S. Ping-Pong Diplomacy
Published on 02/02/2026 at 19:57, 1 hour 7 minutes ago

US federal court grants preliminary injunction allowing Sunrise Wind construction to resume
Published on 02/02/2026 at 19:42, 1 hour 21 minutes ago

EQS-Adhoc: ProSiebenSat.1 publishes preliminary figures for financial year 2025
Published on 02/02/2026 at 19:05, 1 hour 59 minutes ago

Virtual Science AI launches the life science industry's first medical congress AI solution for real-time event conversational intelligence
Published on 02/02/2026 at 19:00, 2 hours 4 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 02/02/2026 at 18:23, 2 hours 41 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:23, 2 hours 41 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Janvier 2026
Published on 02/02/2026 at 18:00, 3 hours 4 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 18:00, 3 hours 4 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 02/02/2026 at 18:00, 3 hours 4 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social

View all LES ECHOS COMFI WIRE